Georgetown University, Lombardi Cancer Center Support Grant Competitive Renewal

描述(由申请人提供)：这是乔治敦隆巴迪综合癌症中心(Lombardi)CCSG第20至24年的续签申请。Lombardi的使命是通过尖端研究、专家和富有同情心的患者护理、对未来癌症专家的教育以及对社区的服务来预防、治疗和治愈癌症。伦巴迪是美国首都和华盛顿大都会地区唯一由NCI指定的癌症中心。哥伦比亚特区是全国癌症死亡率最高的地区之一。因此，显然需要一个由NCI指定的综合性癌症中心，它可以为癌症护理和预防带来有针对性的、基于证据的策略，以帮助改善社区居民的健康。在本申请中，Lombardi由177名成员(113名正式成员)组成，在12个共享资源的支持下参与了6个研究项目，主要设在两个相邻的建筑中。2008年，同行评议的研究年度直接资助总额为5300万美元，其中2850万美元来自NCI。与2002年相比，NCI的资金有了很大的增加。Lombardi临床活动是与Gu的临床合作伙伴MedStar Health，Inc.共同开展的。在02财年，Lombardi临床服务为22,000多名癌症门诊患者提供服务，603名患者参加了Lombardi临床试验。2008年，癌症门诊就诊人数增加到3.9万人次，有1169人接受了干预试验。乔治城大学(GU)坚定不移地致力于Lombardi的成功，2008年1月招聘了一位新主任Louis Weiner医学博士就是一个例证。他也是州立大学肿瘤学系的主席，有权招聘教员，控制空间，并监督资源分配，以支持隆巴迪的使命。最近几个备受瞩目的招聘活动证明了隆巴迪吸引优秀研究人员的能力。隆巴迪研究环境的成功体现在其在基础科学、临床转化研究和人口科学领域的六个研究计划，以及在健康差距和系统医学方面的新的交叉倡议。在当前的资助期间，Lombardi的研究人员发表了近2000篇同行评审的手稿(24%是计划内的，22%是计划间的)，对这项申请中突出的癌症研究领域产生了持续而强大的影响，例如人类乳头瘤病毒疫苗的开发。在CCSG的持续支持下，Lombardi将继续为癌症研究做出杰出的、具有重大影响的贡献。 相关：这是乔治敦隆巴迪综合癌症中心(Lombardi)CCSG的续签申请，该中心由医学博士Louis Weiner领导，为期20至24年。Lombardi的使命是通过尖端研究、专家和富有同情心的患者护理、未来癌症专家的教育以及为社区提供服务来预防、治疗和治愈癌症。隆巴迪研究环境的成功体现在其在基础科学、临床转化研究和人口科学领域的六个研究项目。每个项目都汇集了专注于不同领域的癌症研究人员，以及在健康差异和系统医学方面的新的交叉倡议。在CCSG的持续支持下，Lombardi将继续为癌症研究做出杰出的、有重大影响的贡献。

DESCRIPTION (provided by applicant): This is a renewal application for years 20 to 24 of the Georgetown Lombardi Comprehensive Cancer Center (Lombardi) CCSG. Lombardi's mission is to prevent, treat and cure cancers, through cutting-edge research, expert and compassionate patient care, education of future cancer specialists, and service to the community. Lombardi is the only NCI-designated cancer center in the nation's capital and in the Washington metropolitan area. The District of Columbia has among the highest cancer mortality rates in the country. Thus, there is a clear need for an NCI-designated comprehensive cancer center that can bring a targeted, evidence-based strategy to cancer care and prevention to help improve the health of the community's residents. In the present application, Lombardi comprises 177 members (113 full members), participating in six research programs with the support of 12 shared resources, based primarily in two adjacent buildings. Peer-reviewed research annual direct funding for 2008 totaled $53 million, with $28.5 million coming from the NCI. This represents a significant increase in NCI funding compared with 2002. Lombardi clinical activities are carried out in conjunction with GU's clinical partner, MedStar Health, Inc. In FY02, Lombardi clinical services served more than 22,000 outpatient cancer visits, and 603 patients were enrolled on Lombardi clinical trials. Outpatient cancer visits have increased to 39,000 in 2008, with 1,169 people placed on interventional trials. Georgetown University's (GU) unwavering high level of commitment to the success of Lombardi is exemplified by the recruitment of a new Director, Louis Weiner, M.D., in January 2008. He also chairs the GU Department of Oncology, with the authority to recruit faculty, control space, and oversee resource allocation to support Lombardi's mission. Several recent high-profile recruitments attest to Lombardi's ability to attract outstanding researchers. The success of Lombardi's research environment is demonstrated by its six research programs in the areas of basic science, clinical translational research, and population science, coupled with new cross-cutting initiatives in health disparities and systems medicine. Lombardi's researchers published almost 2,000 peer-reviewed manuscripts (24% intraprogrammatic and 22% interprogrammatic) in the current funding period, exerting a sustained and powerful influence on the cancer research fields highlighted in this application, such as the development of human papillomavirus vaccines. With continued CCSG support, Lombardi will continue to make outstanding, high-impact contributions to cancer research. RELEVANCE: This is a renewal application for years 20 to 24 of the Georgetown Lombardi Comprehensive Cancer Center (Lombardi) CCSG, led by Louis Weiner, M.D. Lombardi's mission is to prevent, treat and cure cancers, through cutting-edge research, expert and compassionate patient care, education of future cancer specialists, and service to the community. The success of Lombardi's research environment is demonstrated by its six research programs in the areas of basic science, clinical translational research, and population science. Each program brings together cancer researchers who focus on distinct areas, coupled with new cross-cutting initiatives in health disparities and systems medicine. With continued CCSG support, Lombardi will continue to make outstanding, high impact contributions to cancer research.